Dose escalated intensity modulated radiotherapy versus standard dose intensity modulated radiotherapy in laryngeal and hypopharyngeal cancer patients

Submission date	Recruitment status No longer recruiting	Prospectively registered		
17/01/2011		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
31/03/2011	Completed	[X] Results		
Last Edited	Condition category	[] Individual participant data		
24/03/2022	Cancer			

Plain English summary of protocol

http://www.cancerhelp.org.uk/trials/a-study-looking-increasing-dose-radiotherapy-treat-cancervoice-box-or-lower-part-of-the-throat-art-deco

Study website

http://www.icr.ac.uk/research/research_sections/clinical_trials/trials_by_disease/head_and_neck/index.shtml

Contact information

Type(s)

Scientific

Contact name

Dr Christopher Nutting

Contact details

Director Head and Neck Unit, Consultant Reader in Oncology Royal Marsden NHS Foundation Trust Head and Neck Unit Royal Marsden Hospital Fulham Road London United Kingdom SW3 6JJ

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

ICR-CTSU/2009/10022

Study information

Scientific Title

A randomised multicentre accelerated radiotherapy study of dose escalated intensity modulated radiotherapy versus standard dose intensity modulated radiotherapy in patients receiving treatment for locally advanced laryngeal and hypopharyngeal cancers

Acronym

ART-DECO

Study objectives

To determine the potential of dose escalated intensity modulated radiotherapy (IMRT) to improve locoregional failure free rate (LRFFR) and laryngeal preservation in patients with locally advanced laryngeal and hypopharyngeal cancers, without increasing the incidence of severe acute and late toxicities to unacceptable levels.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Central London Research Ethics Committee (REC) 4 approved on 18/10/2010 (ref: 10/H0715/48)

Study design

Parallel group phase III multicentre randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Locally advanced squamous cell cancers of the larynx or hypopharynx

Interventions

The dose escalated IMRT (experimental) treatment group will receive 67.2 Gy in 28 fractions (2.4 Gy per fraction) to the involved site and nodal groups and 56 Gy in 28 fractions (2.0 Gy per fraction) to nodal areas at risk of harbouring microscopic disease.

The standard dose IMRT (standard) treatment group will receive 65 Gy in 30 fractions (2.167 Gy per fraction) to the involved site and nodal groups and 54 Gy in 30 fractions (1.8 Gy per fraction) to nodal areas at risk of harbouring microscopic disease.

All patients will receive concomitant cisplatin 100 mg/m2 on day 1 and day 29 of the radiotherapy schedule however within the context of this trial, chemotherapy is not an investigational medicinal product.

Intervention Type

Other

Phase

Phase III

Primary outcome measure

Locoregional failure free rate (LRFFR).

Measured at 1, 2, 3, 4 and 8 weeks post-treatment and at 3, 6, 12, 18 and 24 months post treatment. Patients will then be followed up annually up to 5 years.

Secondary outcome measures

- 1. Laryngo-oesophageal dysfunction free rate
- 2. Overall survival (time from randomisation to death)
- 3. Acute and late toxicities following chemoradiation
- 4. Characteristics of patients who proceed to salvage neck dissection
- 5. Characteristics of patients who fail organ preservation

All of the above will be measured at 1, 2, 3, 4 and 8 weeks post-treatment and at 3, 6, 12, 18 and 24 months post treatment. Patients will then be followed up annually up to 5 years.

6. Patient assessed quality of life, measured using questionnaires administered at baseline, end of radiotherpay treatment, 6 months, 1 year and then annually to 5 years post-treatment

Overall study start date

01/02/2011

Completion date

01/12/2020

Eligibility

Key inclusion criteria

- 1. Aged 16 years or above, either sex
- 2. Histologically confirmed squamous cell cancer of the larynx or hypopharynx

- 3. Chemo-radiotherapy is the investigators treatment of choice. Induction chemotherapy is permitted.
- 4. Locally advanced squamous cell cancer of the larynx or hypopharynx i.e. stage III or IV a/b disease
- 5. World Health Organization (WHO) performance status of 0 or 1
- 6. Creatinine clearance of greater than 50 ml/min
- 7. Must be suitable to attend long term follow-up. All patients participating in the QoL study must have adequate cognitive ability to complete the QoL questionnaires.
- 8. Written informed consent

Patients may undergo surgical biopsy or non-radical surgery prior to study entry.

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

354

Total final enrolment

276

Key exclusion criteria

- 1. Previous radiotherapy to the head and neck region
- 2. Clinical evidence of metastatic disease (Stage IVc)
- 3. Previous malignancy except non-melanoma skin cancer and early stage cancer in remission for at least 5 years following treatment
- 4. Previous or concurrent illness, which in the investigator's opinion would interfere with completion of therapy
- 5. Pre-existing previous speech or swallowing problems unrelated to the diagnosis of cancer
- 6. Large primary tumour, where organ preservation is unrealistic

Date of first enrolment

01/02/2011

Date of final enrolment

20/10/2015

Locations

Countries of recruitment

England

United Kingdom

Study participating centre Head and Neck Unit

London United Kingdom SW3 6JJ

Sponsor information

Organisation

Royal Marsden NHS Foundation Trust (UK)

Sponsor details

Fulham Road London England United Kingdom SW3 6JJ

Sponsor type

Hospital/treatment centre

Website

http://www.royalmarsden.nhs.uk/home

ROR

https://ror.org/0008wzh48

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK (CRUK) (UK) (ref: CRUK/10/018)

Alternative Name(s)

CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

LocationUnited Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		10/07/2021	14/07/2021	Yes	No
Plain English results		10/03/2022	24/03/2022	No	Yes